Eli Lilly signed a deal worth up to $2.25 billion with AI gene-editing company Profluent, extending its aggressive multi-platform bet on AI drug discovery across several distinct technology approaches.
The University of Texas System struck an enterprise-wide deal to expand Abridge's ambient AI scribe across all eight of its health institutions after a pilot saw clinician usage grow 73% in a year.
GSK licensed a cellular-biology foundation model from UK biotech Relation Therapeutics in a deal worth up to $110 million, part of a wider pharma shift toward licensing specialized AI platforms.
Boehringer Ingelheim expanded its partnership with AI drug discovery company Owkin to target oncology and immunology, using federated learning across hospital data networks to find new drug targets.
Zealand Pharma struck a deal worth up to $1.2 billion with AI protein-design company Generate Biomedicines to pursue new obesity treatments, joining a wave of major AI drug discovery partnerships.
Doctors and lawyers are earning up to $400 an hour training AI models with their domain expertise, a fast-growing gig market raising new questions about ethics, quality control, and long-term risk.
AI drug discovery company Iambic Therapeutics completed a $150 million IPO with shares rising, showing investor appetite for AI-native biotechs even as the sector awaits its first approved medicine.
KKR-backed Catalio Capital is seeking $500 million for its second AI healthcare investment fund, a sign specialized healthcare AI investing has stayed resilient even as broader AI funding grows choosier.
Big pharma has committed billions to AI drug discovery deals, but no AI-designed drug has yet reached the market, leaving a growing gap between investment enthusiasm and proven clinical payoff.
Aidoc's CARE foundation model won FDA clearance for 11 new CT triage indications, bringing its total to 14, and the company followed with a $150 million Series E that pushed its total funding past $500 million.